Global $18.3 Bn Atopic Dermatitis Drug Forecast and Market Analysis to 2027 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Atopic
Dermatitis: Global Drug Forecast and Market Analysis to 2027”
report has been added to ResearchAndMarkets.com’s
offering.

The report “Atopic Dermatitis: Global Drug Forecast and Market Analysis
to 2027”, provides key metrics for atopic dermatitis (Epidemiology,
Market Size, Product Pipeline, Key Events, Competitive Analysis) in the
seven major pharmaceutical markets (7MM) covered in this report-the US,
5EU (France, Germany, Italy, Spain, and the UK), and Japan-during the
forecast period from 2017-2027.

Global sales in the atopic dermatitis market are expected to grow to
$18.3B by 2027, at a Compound Annual Growth Rate (CAGR) of 11.1% from
2017-2027. It is estimated that sales of drugs in the atopic dermatitis
market were approximately $6.4B in 2017 in the 7MM (United States,
France, Germany, Italy, Spain, United Kingdom and Japan).

The US was the largest market, with approximately $5.1B in drug sales,
which represented 80% of the total atopic dermatitis market. The 5EU
market contributed $1.1B in sales and Japan contributed sales of $202M
in 2017. It is forecasted that the US to grow to $13.6B, followed by 5EU
(France, Germany, Italy, Spain, United Kingdom) and Japan.

Atopic dermatitis is a widespread chronic inflammatory skin condition
that can affect patients of all ages and is the result of a complex
interplay of environmental, immunological, genetic, and pharmacologic
factors. The atopic dermatitis market has historically remained stagnant
and the pipeline for drugs in late-stage development was lacking, but
recent developments have reignited interest in the treatment of the
disease, especially as the estimated drug-treated population may grow to
24,000,000 people over the next decade.

The atopic dermatitis pipeline has traditionally been focused on topical
therapies, with Pfizer’s Eucrisa being the latest to be approved in
December 2016. Until the launch of Regeneron/Sanofi’s Dupixent in March
2017, severe atopic dermatitis patients had to be prescribed systemic
immunomodulators, which are associated with a slew of side effects.
However, the arrival of Dupixent, a first-in-class monoclonal antibody
(mAb), addressed the unmet needs of these severe patients. The pipeline
mostly comprises systemic therapies targeting the moderate-to-severe
population.

Reasons to buy

• Develop and design your in-licensing and out-licensing strategies
  through a review of pipeline products and technologies, and by
  identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and
  driving the global atopic dermatitis therapeutics market.
• Drive revenues by understanding the key trends, innovative products
  and technologies, market segments, and companies likely to impact the
  global atopic dermatitis therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding
  the competitive landscape and by analyzing the performance of various
  competitors.
• Identify emerging players with potentially strong product portfolios
  and create effective counter-strategies to gain a competitive
  advantage.
• Track drug sales in the global atopic dermatitis therapeutics market
  from 2017-2027.
• Organize your sales and marketing efforts by identifying the market
  categories and segments that present maximum opportunities for
  consolidations, investments and strategic partnerships.

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Atopic Dermatitis: Executive Summary

2.1 Atopic Dermatitis Market to Experience Strong Growth from 20172027

2.2 Late-Stage Pipeline Product Launches Will Result in New Players
Establishing Themselves

2.3 Persistent Unmet Needs Will Be Addressed Over the Forecast Period

2.4 Interleukin Inhibitors and Janus Kinase Inhibitors Dominate the
Atopic Dermatitis Pipeline

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification or Staging Systems

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.5 Epidemiological Forecast for Atopic Dermatitis (20172027)

5.5.1 One-Year Total Prevalent Cases of Atopic Dermatitis

5.5.2 Age-Specific One-Year Total Prevalent Cases of Atopic Dermatitis

5.5.3 Sex-Specific One-Year Total Prevalent Cases of Atopic Dermatitis

5.5.4 One-Year Total Prevalent Cases of Atopic Dermatitis by Severity

5.5.5 One-Year Diagnosed Prevalent Cases of Atopic Dermatitis

5.5.6 Age-Specific One-Year Diagnosed Prevalent Cases of Atopic
Dermatitis

5.5.7 Sex-Specific One-Year Diagnosed Prevalent Cases of Atopic
Dermatitis

5.5.8 One-Year Diagnosed Prevalent Cases of Atopic Dermatitis by Severity

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.2 US

6.3 5EU

6.4 Japan

7 Competitive Assessment

7.1 Overview

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Topical Treatments Without Side Effects

8.3 A Drug that Effectively Controls Patients’ Pruritus

8.4 Addressing Heterogeneity in the Pathophysiology of Atopic Dermatitis

8.5 Improved Patient Compliance and Education

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Company Profiles

10.3.1 LEO Pharma

10.3.2 Pfizer

10.3.3 Regeneron

10.3.4 AbbVie

10.3.5 Dermira

10.3.6 Eli Lilly

10.3.7 Galderma

10.3.8 Incyte

10.4 Other Players

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

12 Appendix

Companies Mentioned

• Sanofi
• Regeneron
• LEO Pharma
• Pfizer
• AbbVie
• Dermira
• Eli Lilly
• Galderma
• Incyte
• Bausch Health
• Meda

For more information about this report visit https://www.researchandmarkets.com/r/mc91nd

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Immune
Disorders Drugs, Dermatological
Drugs